Inventiva (NASDAQ:IVA) Shares Gap Up – What’s Next?

Inventiva S.A. Sponsored ADR (NASDAQ:IVA)’s stock price gapped up before the market opened on Wednesday . The stock had previously closed at $4.77, but opened at $4.92. Inventiva shares last traded at $4.84, with a volume of 159,531 shares traded.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. Cantor Fitzgerald assumed coverage on Inventiva in a report on Friday, July 17th. They issued an “overweight” rating on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inventiva in a report on Friday, July 17th. Three research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $15.38.

Inventiva Trading Up 1.1%

The business’s 50-day simple moving average is $4.43 and its 200-day simple moving average is $5.05.

Institutional Investors Weigh In On Inventiva

A number of institutional investors and hedge funds have recently bought and sold shares of IVA. Creative Planning purchased a new position in Inventiva during the second quarter worth $32,000. Virtu Financial LLC purchased a new stake in shares of Inventiva in the fourth quarter valued at $60,000. XTX Topco Ltd acquired a new stake in shares of Inventiva during the fourth quarter valued at $84,000. NewEdge Advisors LLC acquired a new stake in shares of Inventiva during the third quarter valued at $116,000. Finally, Cerity Partners LLC purchased a new stake in Inventiva during the 4th quarter worth about $93,000. Hedge funds and other institutional investors own 19.06% of the company’s stock.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical?stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.